New triple therapy aims to tame immune side effects in advanced melanoma
NCT ID NCT03999749
First seen Mar 28, 2026 · Last updated Apr 24, 2026 · Updated 3 times
Summary
This study tests a three-drug combination for people with advanced melanoma that cannot be removed by surgery. The goal is to see if adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe immune-related side effects while still controlling the cancer. About 71 participants will receive the drugs over several months, with the main focus on safety and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
NYU Langone Health
New York, New York, 10016, United States
-
The Angeles Clinic
Los Angeles, California, 90025, United States
Conditions
Explore the condition pages connected to this study.